Cargando…
Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes
BACKGROUND: SGLT2 inhibitors are a new class of drugs that act by inhibiting glucose reabsorption in the proximal renal tubules. Many trials have demonstrated their effectiveness in reducing glycated hemoglobin (HbA1c) and weight, but they have never been examined in Arab or Emirati populations. MET...
Autores principales: | Bashier, Alaaeldin, Khalifa, Azza Abdulaziz, Rashid, Fauzia, Abdelgadir, Elamin Ibrahim, Al Qaysi, Amina Adil, Ali, Razan, Eltinay, Ahmed, Nafach, Jalal, Alsayyah, Fatima, Alawadi, Fatheya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412523/ https://www.ncbi.nlm.nih.gov/pubmed/28496550 http://dx.doi.org/10.14740/jocmr2976w |
Ejemplares similares
-
SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018) -
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial
por: Bashier, Alaaeldin M. K., et al.
Publicado: (2015) -
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
por: Bashier, Alaaeldin, et al.
Publicado: (2019) -
Peri-portal lymphedema in association with an acute adrenal insufficiency: case report
por: Abdelgadir, Elamin Ibrahim Elamin, et al.
Publicado: (2014) -
Effect of Metformin on Different Non-Diabetes Related Conditions, a Special Focus on Malignant Conditions: Review of Literature
por: Abdelgadir, Elamin, et al.
Publicado: (2017)